Implant to help adults with severe emphysema

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

IAB-2 is an open-label, multicenter, prospective trial that implants an artificial bronchus device in adults with severe COPD/emphysema and follows them for safety and functional outcomes. There is no control or sham group; all enrolled participants receive the device. The trial is planned at multiple sites across the United States and at centers in the Netherlands, Germany, and Brazil. Key eligibility includes severe airflow obstruction, significant emphysema on CT, reduced exercise capacity, and a period of smoking abstinence prior to enrollment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed Informed Consent.
2. Diagnosis of COPD/emphysema.
3. At least 22-years of age.
4. 18 ≤ BMI ≤ 32.
5. 6-minute walk Distance between 100-meters and 400-meters at baseline exam.
6. Stable disease with less than 10-mg prednisone (or equivalent) daily
7. Non-smoking for 4-months prior to screening interview (including tobacco, vaping, marijuana, etc.).
8. FEV1 between 15% and 50% of predicted value at baseline exam.
9. FEV1/FVC \<70%.
10. Subject has ≥25% emphysema destruction score in each lung defined by areas of low attenuation \<-950 HU, as determined by CT core lab.
11. Subject has homogeneous or heterogeneous emphysema, and at least one lung has a 15% difference between upper and lower lobes in emphysema destruction score (\< -950HU) as determined by CT core lab.
12. RV \> 175% of predicted value.
13. mMRC score ≥ 2.

Exclusion Criteria:

* 1\. Currently participating in another clinical study that involves surgery, interventional or pharmaceutical treatment..

  2\. α-1 Antitrypsin deficiency 3. Women of child-bearing potential. 4. More than 2 COPD exacerbation episodes requiring hospitalization in the last year prior to screening.

  5\. Any COPD exacerbations requiring hospitalization within 6-weeks of planned intervention.

  6\. Two or more instances of pneumonia episodes requiring hospitalization in the last year prior to screening.

  7\. Clinically significant mucus production or chronic bronchitis. 8. Myocardial Infarction or unstable / uncontrolled congestive heart failure within 6-months of screening.

  9\. Prior lung transplant, LVRS, bullectomy, lobectomy or endoscopic lung volume reduction (ELVR).

  10\. Clinically significant bronchiectasis. 11. Unable to safely discontinue anti-coagulants or platelet activity inhibitors for 7-days.

  12\. Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure \>45 mm Hg) or evidence or history of cor pulmonale as determined by recent echocardiogram (completed within the last 3-months prior to screening visit). Note: the echocardiogram is not a required screening procedure.

  13\. Suspected malignant pulmonary nodule or other lung cancer. 14. HRCT collected per CT scanning protocol within the last 6-months of screening date and evaluated by clinical site personnel using 3D segmentation software shows:
  1. Large bullae encompassing greater than 30% of either lung
  2. Insufficient landmarks to evaluate the CT study using the software as it is intended
  3. All lobes are less than 25% parenchyma diseased (\< -950 HU) 15. Any cardiac comorbidity which the PI believes would compromise the safety of the patient after an IAB implant.

     16\. TLC \< 100% predicted at screening. 17. DLCO \< 15% or \> 50% of predicted value at screening. 18. PaCO2 \> 50 mm Hg at screening. 19. PaO2 \< 45 mm Hg in room air at screening. 20. Plasma cotinine level \> 13.7 ng/ml or carboxyhemoglobin (arterial or ear lobe capillary) \>2.5% at screening.

     21\. Current diagnosis of substance abuse disorder. 22. Current diagnosis of any of the following: Major Depressive Disorder (MDD), Schizoaffective Disorder, Schizophrenia, Borderline Personality Disorder, Bipolar Disorder.

     23\. Any other conditions, which, in the opinion of the Investigator, would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study.

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting
• Northwestern University
  Chicago, Illinois, United States Recruiting
• Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States Recruiting
• Medical College of Wisconsin
  Milwaukee, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Adnan Majid, MD — Beth Israel Deaconess Medical Center
• Study coordinator: VP Clincal Operations
• Email: tkruger@pulmair.com
• Phone: 858-369-0000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Endobronchial thermal liquid ablation for treating emphysema

  This study is testing a new treatment called endobronchial thermal liquid ablation to see if it can safely help people with severe emphysema breathe better and improve their quality of life.

  Recruiting at 2 sites Morair Medtech, LLC · Vienna, Austria and 6 other locations · NCT06655428

• Implantable Artificial Bronchus 50 Flex for adults with severe emphysema

  This tests a small implant called the IAB 50 Flex to see if it is safe and helps adults with severe COPD or emphysema breathe and move more easily.

  Recruiting at 2 sites Pulmair Medical, Inc. · Limoges and 1 other locations · NCT07086339

• Multidisciplinary sarcopenia clinic to diagnose and treat muscle loss from COPD

  This project will try a multidisciplinary sarcopenia clinic to see if it improves muscle mass, function, and overall health for COPD patients with CT-confirmed muscle loss after a hospitalization.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07059637

• Bronchoscopic release of trapped air in hyperinflated emphysematous lungs

  This trial tests if placing permanent Apreo BREATHE airway scaffold implants by bronchoscopy, together with usual medical care, helps adults with COPD and emphysema who remain short of breath from lung hyperinflation.

  Recruiting at 23 sites Apreo Health, Inc. · Birmingham, Alabama and 22 other locations · NCT06891755

• Lung cancer screening program for patients with COPD or emphysema

  This study is testing if regular lung cancer screenings can help people with COPD or emphysema catch lung cancer earlier and live longer.

  Recruiting at 2 sites Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Madrid and 1 other locations · NCT06690385

• Using breath analysis to identify multiple lung diseases

  This study is testing if analyzing breath samples can help identify different lung diseases like lung cancer and COPD in a large group of 10,000 people.

  Recruiting ChromX Health · Guangzhou, Guangdong · NCT06528418

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.